ArticleBMC cancer2023

Comparative efficacy and safety of different combinations of three CDK4/6 inhibitors with endocrine therapies in HR+/HER-2 - metastatic or advanced breast cancer patients: a network meta-analysis.

Yiyuan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.